Barriers to the access of bevacizumab in patients with solid tumors and the potential impact of biosimilars: A physician survey

Pharmaceuticals

Volumn 10, Issue 1, 2017, Pages

  Monk, Bradley J ^a   Lammers, Philip E ^b   Cartwright, Thomas ^c   Jacobs, Ira ^d  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b MEHARRY MEDICAL COLLEGE   (United States)

^c Florida Cancer Affiliates   (United States)

^d PFIZER INC   (United States)

Author keywords

Access to health care; Bevacizumab; Biosimilars; Colorectal cancer; Non small cell lung cancer; Ovarian cancer

Indexed keywords

BEVACIZUMAB; BIOSIMILAR AGENT;

ARTICLE; BRAZIL; BREAST CANCER; CANCER PATIENT; DRUG COST; DRUG EFFICACY; DRUG SAFETY; EUROPE; GLIOBLASTOMA; HEALTH CARE ACCESS; HEALTH CARE NEED; HEMATOLOGIST; HUMAN; METASTATIC COLORECTAL CANCER; MEXICO; MULTIPLE CYCLE TREATMENT; NON SMALL CELL LUNG CANCER; ONCOLOGIST; OVARY CANCER; PRESCRIPTION; QUESTIONNAIRE; REIMBURSEMENT; SOLID TUMOR; TREATMENT OUTCOME; UNITED STATES;

EID: 85011556605     PISSN: None     EISSN: 14248247     Source Type: Journal    
DOI: 10.3390/ph10010019     Document Type: Article

References (35)

1. Avastin® (bevacizumab) US prescribing information. Available online: http://www.gene.com/download/pdf/avastin_prescribing.pdf (accessed 22 February 2016).
2. Presta, L.G.; Chen, H.; O’Connor, S.J.; Chisholm, V.; Meng, Y.G.; Krummen, L.; Winkler, M.; Ferrara, N. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 1997, 57, 4593–4599.
3. Summary of Product Characteristics: Avastin (bevacizumab). Available online: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000582/WC500029260.pdf (accessed 22 February 2016).
4. Ferrara, N. Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am. J. Physiol. Cell Physiol. 2001, 280, C1358–C1366.
5. Fox, W.D.; Higgins, B.; Maiese, K.M.; Drobnjak, M.; Cordon-Cardo, C.; Scher, H.I.; Agus, D.B. Antibody to vascular endothelial growth factor slows growth of an androgen-independent xenograft model of prostate cancer. Clin. Cancer Res. 2002, 8, 3226–3231.
6. Mabuchi, S.; Terai, Y.; Morishige, K.; Tanabe-Kimura, A.; Sasaki, H.; Kanemura, M.; Tsunetoh, S.; Tanaka, Y.; Sakata, M.; Burger, R.A., et al. Maintenance treatment with bevacizumab prolongs survival in an in vivo ovarian cancer model. Clin. Cancer Res. 2008, 14, 7781–7789.
7. Burger, R.A.; Brady, M.F.; Bookman, M.A.; Fleming, G.F.; Monk, B.J.; Huang, H.; Mannel, R.S.; Homesley, H.D.; Fowler, J.; Greer, B.E., et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N. Engl. J. Med. 2011, 365, 2473–2483.
8. Hurwitz, H.; Fehrenbacher, L.; Novotny, W.; Cartwright, T.; Hainsworth, J.; Heim, W.; Berlin, J.; Baron, A.; Griffing, S.; Holmgren, E., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 2004, 350, 2335–2342.
9. Miller, K.; Wang, M.; Gralow, J.; Dickler, M.; Cobleigh, M.; Perez, E.A.; Shenkier, T.; Cella, D.; Davidson, N.E. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N. Engl. J. Med. 2007, 357, 2666–2676.
10. Sandler, A.; Gray, R.; Perry, M.C.; Brahmer, J.; Schiller, J.H.; Dowlati, A.; Lilenbaum, R.; Johnson, D.H. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med. 2006, 355, 2542–2550.
11. Tewari, K.S.; Sill, M.W.; Long, H.J., 3rd; Penson, R.T.; Huang, H.; Ramondetta, L.M.; Landrum, L.M.; Oaknin, A.; Reid, T.J.; Leitao, M.M., et al. Improved survival with bevacizumab in advanced cervical cancer. N. Engl. J. Med. 2014, 370, 734–743.
12. Friedman, H.S.; Prados, M.D.; Wen, P.Y.; Mikkelsen, T.; Schiff, D.; Abrey, L.E.; Yung, W.K.; Paleologos, N.; Nicholas, M.K.; Jensen, R., et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J. Clin. Oncol. 2009, 27, 4733–4740.
13. Baer, W.H.; Maini, A.; Jacobs, I. Barriers to the Access and Use of Rituximab in Patients with Non- Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia: A Physician Survey. Pharmaceuticals 2014, 7, 530–544.
14. Cherny, N.; Sullivan, R.; Torode, J.; Saar, M.; Eniu, A. European consortium study on the availability, outof- pocket costs and accessibility of anti-neoplastic medicines in Europe. Ann. Oncol. 2016, 27, 1423–1443.
15. Lammers, P.; Criscitiello, C.; Curigliano, G.; Jacobs, I. Barriers to the Use of Trastuzumab for HER2+ Breast Cancer and the Potential Impact of Biosimilars: A Physician Survey in the United States and Emerging Markets. Pharmaceuticals 2014, 7, 943–953.
16. Goldstein, D.A.; El-Rayes, B.F. Considering Efficacy and Cost, Where Does Ramucirumab Fit in the Management of Metastatic Colorectal Cancer? Oncologist 2015, 20, 981–982.
17. Daller, J. Biosimilars: A consideration of the regulations in the United States and European union. Regul. Toxicol. Pharmacol. 2016, 76, 199–208.
18. US Congress. Biologics Price Competition and Innovation Act of 2009. Available online: https://www.congress.gov/111/plaws/publ148/PLAW-111publ148.pdf (accessed 26 January 2017).
19. A health-system pharmacist’s guide to biosimilars: regulatory, scientific, and practical considerations. Available online: http://ashpadvantagemedia.com/downloads/biosimcentral_guidelines.pdf (accessed 4 February 2016).
20. Guideline on similar biological medicinal products. Available online: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/10/WC500176768.pdf (accessed 22 February 2016).
21. Scientific considerations in demonstrating biosimilarity to a reference product: guidance for industry. Available online: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm291128.pdf (accessed 22 February 2016).
22. Expert committee on biological standardization. Guidelines on evaluation of similar biotherapeutic products (SBPs). Available online: http://www.who.int/biologicals/areas/biological_therapeutics/BIOTHERAPEUTICS_FOR_WEB_22APRIL2010.pdf (accessed 22 February 2016).
23. Biosimilars: 11 Drugs to Watch. Available online: http://www.genengnews.com/insight-andintelligence/biosimilars-11-drugs-to-watch/77900135 (accessed 12 May 2016).
24. Biosimilars of bevacizumab. Available online: http://www.gabionline.net/Biosimilars/General/Biosimilarsof-bevacizumab (accessed 29 April 2016).
25. Goldstein, D.A.; Clark, J.; Tu, Y.; Zhang, J.; Fang, F.; Goldstein, R.M.; Stemmer, S.M.; Rosenbaum, E. Global differences in cancer drug prices: A comparative analysis. J. Clin. Oncol. 2016, 34, abstr LBA6500.
26. Besse, B.; Adjei, A.; Baas, P.; Meldgaard, P.; Nicolson, M.; Paz-Ares, L.; Reck, M.; Smit, E.F.; Syrigos, K.; Stahel, R., et al. 2nd ESMO Consensus Conference on Lung Cancer: Non-small-cell lung cancer firstline/ second and further lines of treatment in advanced disease. Ann. Oncol. 2014, 25, 1475–1484.
27. Masters, G.A.; Temin, S.; Azzoli, C.G.; Giaccone, G.; Baker, S., Jr.; Brahmer, J.R.; Ellis, P.M.; Gajra, A.; Rackear, N.; Schiller, J.H., et al. Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J. Clin. Oncol. 2015, 33, 3488–3515.
28. Clinical practice guidelines in oncology (NCCN guidelines): Colon cancer. Version 2.2016. Available online: https://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site (accessed 29 April 2016).
29. Clincal practice guidelines in oncology (NCCN guidelines): Non-small cell lung cancer. Version 4.2016. Available online: https://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site (accessed 29 April 2016).
30. Reck, M.; Popat, S.; Reinmuth, N.; De Ruysscher, D.; Kerr, K.M.; Peters, S. Metastatic non–small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2014, 25, 27–39.
31. Van Cutsem, E.; Cervantes, A.; Nordlinger, B.; Arnold, D. Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2014, 25, 1–9.
32. EU approves Roche’s avastin plus chemotherapy for women with advanced cervical cancer [Media release]. Available online: http://www.roche.com/media/store/releases/med-cor-2015-04-08.htm (accessed 23 June 2016).
33. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. Available online: http://globocan.iarc.fr (accessed 23 June 2016).
34. Gascon, P.; Tesch, H.; Verpoort, K.; Rosati, M.S.; Salesi, N.; Agrawal, S.; Wilking, N.; Barker, H.; Muenzberg, M.; Turner, M. Clinical experience with Zarzio® in Europe: What have we learned? Supportive Care in Cancer. 2013, 21, 2925–2932.
35. Sun, D.; Andayani, T.M.; Altyar, A.; MacDonald, K.; Abraham, I. Potential cost savings from chemotherapy-induced febrile neutropenia with biosimilar filgrastim and expanded access to targeted antineoplastic treatment across the European Union G5 countries: a simulation study. Clinical Therapeutics. 2015, 37, 842–857.